Text Size

Monoamine Transporter Function and Autonomic Regulation During Psychodynamic Psychotherapy

This study has been completed.
Sponsor:
Collaborator:
University of Eastern Finland
Information provided by (Responsible Party):
Taru Grohn, Kuopio University Hospital
ClinicalTrials.gov Identifier:
NCT00594711
First received: January 7, 2008
Last updated: October 28, 2011
Last verified: October 2011
History of Changes
  Purpose

Outcome of psychodynamic psychotherapy measured by [123I] nor-B-CIT SPET imaging

Background Psychodynamic psychotherapy is a widely practised form of psychotherapy in the treatment of depression. There is evidence that serotonin transporter (SERT) densities are altered in depression. Preliminary observations have suggested that SERT function may recover in connection with dynamic psychotherapy.

The objective was to determine whether SERT densities change in relation to clinical recovery during psychodynamic psychotherapy.


Condition
Depression

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective

Resource links provided by NLM:

MedlinePlus related topics: Depression
U.S. FDA Resources

Further study details as provided by Kuopio University Hospital:

Biospecimen Retention:   Samples With DNA

DNA, creatine, B-vitamin,BP from blood samples.


Enrollment: 26
Study Start Date: January 2000
Study Completion Date: December 2008
Groups/Cohorts
1
Case-group
2
Control-group

Detailed Description:

N=26

Method Twenty six drug-naïve currently depressed (moderate/severe) patients with no previous treatment were recruited for the study. The baseline study included a group of 18 healthy controls. The patients were randomised into psychotherapy and waiting-list control groups. For controls, psychotherapy was started after a 6-month waiting period. [123I] nor-B-CIT SPET imaging was performed at baseline and after 12 months of psychotherapy. For the controls, additional imaging was performed after the 6-month waiting period.

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patiens of clinic

Criteria

Inclusion Criteria:

  • depression

Exclusion Criteria:

  • antidepressive medication
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00594711

Sponsors and Collaborators
Kuopio University Hospital
University of Eastern Finland
Investigators
Principal Investigator: Pirjo Saarinen, Ph.D. Kuopio University Hospital
Study Director: Johannes Lehtonen, Ph.D Kuopio University Hospital
Study Chair: Lehto Soili, MD Kuopio University Hospital
Study Chair: Minna Valkonen-Korhonen, Ph.D Kuopio University
Study Chair: Pasi Ahola, MD Kuopio University
Study Chair: Mikko Joensuu, MD Kuopio University Hospital
Study Chair: Tommi Tolmunen, Ph.D. Kuopio University Hospital
  More Information

No publications provided

Responsible Party: Taru Grohn, Pirjo Saarinen, Kuopio University Hospital
ClinicalTrials.gov Identifier: NCT00594711     History of Changes
Other Study ID Numbers: KUH5703410, 118/9/00
Study First Received: January 7, 2008
Last Updated: October 28, 2011
Health Authority: Finland: Ethics Committee

Keywords provided by Kuopio University Hospital:
Psychotherapy
depression

Additional relevant MeSH terms:
Depression
Depressive Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders

ClinicalTrials.gov processed this record on May 21, 2013